Cargando…

Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema

Macular peeling combined or followed by intravitreal dexamethasone implant (DEX-i) was recommended as an efficacy approach for tractional diabetic macular edema (tDME). Knowing the synergistic effect of cataract surgery and DEX-i one month earlier in eyes with DME, we compared Epiretinal Membrane/In...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignatelli, Francesco, Niro, Alfredo, Fallico, Matteo, Passidomo, Fedele, Gigliola, Samuele, Nacucchi, Annalisa, Bonfiglio, Vincenza, Reibaldi, Michele, Addabbo, Giuseppe, Avitabile, Teresio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097727/
https://www.ncbi.nlm.nih.gov/pubmed/37045880
http://dx.doi.org/10.1038/s41598-023-32780-5
_version_ 1785024634481016832
author Pignatelli, Francesco
Niro, Alfredo
Fallico, Matteo
Passidomo, Fedele
Gigliola, Samuele
Nacucchi, Annalisa
Bonfiglio, Vincenza
Reibaldi, Michele
Addabbo, Giuseppe
Avitabile, Teresio
author_facet Pignatelli, Francesco
Niro, Alfredo
Fallico, Matteo
Passidomo, Fedele
Gigliola, Samuele
Nacucchi, Annalisa
Bonfiglio, Vincenza
Reibaldi, Michele
Addabbo, Giuseppe
Avitabile, Teresio
author_sort Pignatelli, Francesco
collection PubMed
description Macular peeling combined or followed by intravitreal dexamethasone implant (DEX-i) was recommended as an efficacy approach for tractional diabetic macular edema (tDME). Knowing the synergistic effect of cataract surgery and DEX-i one month earlier in eyes with DME, we compared Epiretinal Membrane/Inner Limiting Membrane (ERM/ILM) peeling preceded by DEX-i one month before versus ERM/ILM peeling alone for the treatment of tDME. A retrospective study on patients affected by tDME who underwent ERM/ILM peeling one month after DEX-i (n = 11; Group A) or ERM/ILM peeling alone (n = 10; Group B) was performed. Longitudinal comparison of best-correct visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP) between the time of surgery (T(0)) and each time point (months 1,3,5,6) within and among the groups were assessed. To evaluate the repeated measurements of BCVA, CRT, and IOP, a linear mixed-effects model was used. In Group A, DEX-i significantly improved mean BCVA and CRT (P < 0.001) just after 1 month (T(0)). After ERM/ILM peeling, mean BCVA and CRT significantly improved from month 1 in Group A and month 3 in Group B. Mixed model revealed a significant difference in BCVA (P ≤ 0.0001) and CRT (P ≤ 0.02) at different time-points among the groups with better results in Group A. Neither complications nor uncontrolled IOP increase was detected. ERM/ILM peeling confirmed its effectiveness in treating tDME. DEX-i performed one month before surgery seemed to be a safe approach and ensured a greater and faster recovery considering functional and tomographic parameters.
format Online
Article
Text
id pubmed-10097727
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100977272023-04-14 Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema Pignatelli, Francesco Niro, Alfredo Fallico, Matteo Passidomo, Fedele Gigliola, Samuele Nacucchi, Annalisa Bonfiglio, Vincenza Reibaldi, Michele Addabbo, Giuseppe Avitabile, Teresio Sci Rep Article Macular peeling combined or followed by intravitreal dexamethasone implant (DEX-i) was recommended as an efficacy approach for tractional diabetic macular edema (tDME). Knowing the synergistic effect of cataract surgery and DEX-i one month earlier in eyes with DME, we compared Epiretinal Membrane/Inner Limiting Membrane (ERM/ILM) peeling preceded by DEX-i one month before versus ERM/ILM peeling alone for the treatment of tDME. A retrospective study on patients affected by tDME who underwent ERM/ILM peeling one month after DEX-i (n = 11; Group A) or ERM/ILM peeling alone (n = 10; Group B) was performed. Longitudinal comparison of best-correct visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP) between the time of surgery (T(0)) and each time point (months 1,3,5,6) within and among the groups were assessed. To evaluate the repeated measurements of BCVA, CRT, and IOP, a linear mixed-effects model was used. In Group A, DEX-i significantly improved mean BCVA and CRT (P < 0.001) just after 1 month (T(0)). After ERM/ILM peeling, mean BCVA and CRT significantly improved from month 1 in Group A and month 3 in Group B. Mixed model revealed a significant difference in BCVA (P ≤ 0.0001) and CRT (P ≤ 0.02) at different time-points among the groups with better results in Group A. Neither complications nor uncontrolled IOP increase was detected. ERM/ILM peeling confirmed its effectiveness in treating tDME. DEX-i performed one month before surgery seemed to be a safe approach and ensured a greater and faster recovery considering functional and tomographic parameters. Nature Publishing Group UK 2023-04-12 /pmc/articles/PMC10097727/ /pubmed/37045880 http://dx.doi.org/10.1038/s41598-023-32780-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pignatelli, Francesco
Niro, Alfredo
Fallico, Matteo
Passidomo, Fedele
Gigliola, Samuele
Nacucchi, Annalisa
Bonfiglio, Vincenza
Reibaldi, Michele
Addabbo, Giuseppe
Avitabile, Teresio
Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
title Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
title_full Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
title_fullStr Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
title_full_unstemmed Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
title_short Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
title_sort mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097727/
https://www.ncbi.nlm.nih.gov/pubmed/37045880
http://dx.doi.org/10.1038/s41598-023-32780-5
work_keys_str_mv AT pignatellifrancesco midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT niroalfredo midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT fallicomatteo midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT passidomofedele midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT gigliolasamuele midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT nacucchiannalisa midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT bonfigliovincenza midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT reibaldimichele midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT addabbogiuseppe midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema
AT avitabileteresio midtermsafetyandeffectivenessofmacularpeelingonemonthafterintravitrealdexamethasoneimplantfortractionaldiabeticmacularedema